Glycogen synthase kinase-3 and cancer: good cop, bad cop?
Dogma held that inhibition of the pleiotropic protein kinase glycogen synthase kinase-3 (GSK-3) was procarcinogenic due to its natural repression of beta-catenin. Now, Wang et al. have found the reverse in certain leukemias, possibly paving the way for small-molecule GSK-3 inhibitors as selective anticancer agents.
Patel
Satish
S
Samuel Lunenfeld Research Institute, Toronto, ON, Canada.
Woodgett
Jim
J
D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005786:Gene Expression Regulation / Q000187:drug effects*; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects; D051176:beta Catenin / Q000378:metabolism
D004791:Enzyme Inhibitors; D051176:beta Catenin; D038362:Glycogen Synthase Kinase 3